While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.

Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.

Meanwhile, Bristol’s other competition in this disease looks set to come from China.

Meanwhile, Lilly gets in on the next-gen KRAS action.

The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.

Competitors have given up on monotherapies in this use, but GenFleet wants to buck the trend.

The company is setting up another battle with Bristol Myers Squibb, while Amgen has different plans.

April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.